Skip to main content
. 2005 Dec 14;25(50):11495–11503. doi: 10.1523/JNEUROSCI.3697-05.2005

Figure 5.

Figure 5.

FcRn-dependent clearance of endogenous Aβ in APPsw+/– mice by centrally administered 4G8. A, Intrahippocampal 4G8 (2 μg/0.5 μl) reduces Aβ immunostaining 24 h after injection in 24-month-old Tg2576 mouse (top; ipsi) compared with nonimmune IgG-treated contralateral hippocampus (bottom; contra). B, 4G8 (2 μg/0.5μl) was injected into the ipsilateral hippocampus in 24-month-old Tg2576 mouse 30 min after αFcRn (anti-FcRn antibody; 10 μg/0.5 μl) (top) or vehicle (bottom; contralateral hippocampus). C, 4G8 F(ab′)2 (2 μg/0.5 μl) injected into the hippocampus in 24-month-old Tg2576 mouse (top) versus vehicle-treated contralateral hippocampus (bottom). Scale bar, 350 μm. D–F, Aβ load (D), Aβ40(E), and Aβ42 (F) levels: the percentage change (%) in the ipsilateral versus contralateral hippocampus in Tg2576 mice. *p < 0.05. G, H, TBS-soluble Aβ oligomers (G) and thioflavin S-positive amyloid load (H) in 4G8-treated (ipsilateral) versus vehicle-treated (contralateral) hippocampus in 24-month-old Tg2576 mice at 24 h. Mean ± SEM; n = 5 mice per group and 6–8 sections close to the injection site per mouse. I, 125I-4G8 F(ab′)2 (40 nm) and 14C-inulin brain retention 30 min after brain ISF microinjection of the tracer mixture. Mean ± SEM; n = 3. NS, Not significant.